S
Silexion Therapeutics Corp (SLXN)
NCM – Real Time Price. Currency in USD
2.75
+0.02 (0.73%)
At close: Jun 26, 2026, 4:00 PM EDT
2.75
0.00 (0.00%)
After-hours: Jun 26, 2026, 7:17 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.75
+0.02 (0.73%)
At close: Jun 26, 2026, 4:00 PM EDT
2.75
0.00 (0.00%)
After-hours: Jun 26, 2026, 7:17 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Company's cash reserves $2.4M significantly exceed its total debt $2.0M, ensuring strong financial flexibility
Total current assets $4.1M are just enough to cover Total current liabilities $4.1M, indicating tight liquidity
Debt-to-equity ratio (6.8) far exceeds the industry average, reflecting over-leverage
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$3.6M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 1.00 | 6.05 | 7.0 | |
| Quick ratio | 1.00 | 5.63 | 7.0 | |
| Debt to Equity | 6.84 | 0.30 | 2.0 | |
| Debt to Assets | 0.43 | 1.04 | 5.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 4.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | -45K | -25K | -14K | -12K |
| Operating Income | -1M | -5M | -13M | -12M | -13M |
| Net Income | 584K | -5M | -16M | -12M | -13M |
| EBITDA | -1M | -5M | -13M | -12M | -13M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 50.93 | 5.5 |
| Next quarter | N/A | 47.22 | 5.5 |
| Current year | N/A | 44.98 | 5.5 |
| Next year | N/A | 58.82 | 5.5 |
| Weighted average score | 5.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 38.06 | 64.36 | -20.8 | 7.8 |
| Y/Y | 999 | -57.51 | 78.21 | -48.26 | 5.5 |
| 3y average | 999 | -383.77 | N/A | -256.72 | 3.3 |
| 5y average | 999 | -251.91 | N/A | -477.68 | 3.3 |
| Weighted average score | 5.0 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |